Stephanie Isaia

Stephanie Isaia is an associate at Goodwin and a member of its Life Sciences group. Stephanie advises public and private pharmaceutical, biotechnology, and medical device companies in connection with mergers and acquisitions and other complex and strategic transactions. Stephanie also advises clients on corporate governance and securities law matters.

Stephanie’s notable representations include:

• A public biotechnology company focused on delivering innovative precision therapies, in its $53 million sale to a leading late-stage, clinical biotechnology company*
• A public online mobile multiplayer video game competition platform, in its $157 million acquisition of a privately held AI-enabled mobile marketing platform company*
• A public medical technology company focused on obesity treatment, in its $112 million sale to a medical device company* 
• A biopharmaceutical company focused on life-threatening food allergies, in its $2.6 billion sale to an international food manufacturer*
• A public clinical-stage biopharmaceutical rare disease company, in its $2.1 billion sale to a multinational biopharmaceutical company*
• A privately held medical device company dedicated to pain relief, in its $120 million sale, with $100 million in contingent payments, to a public non-opioid pain management company*
• A clinical diagnostic testing company, in its $22 million acquisition of a genetic testing software company*
• A public medical device company, in its €29.8 million acquisition of a private medical device company focused on ventilation based in Germany*

*Denotes experience prior to joining Goodwin

Prior to joining Goodwin, Stephanie was an associate at Latham & Watkins LLP and Troutman Pepper LLP.